Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. - Wikidata - awgldk - TriplyDB

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

http://www.wikidata.org/entity/Q35164218

about

Crizotinib resistance: implications for therapeutic strategies New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.ALK: a tyrosine kinase target for cancer therapy.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination.Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases.Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation.Understanding and targeting resistance mechanisms in NSCLC.Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead.Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.Targeted therapy of brain metastases: latest evidence and clinical implications.Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.Tumor biomarker testing in non-small-cell lung cancer: A decade of change.Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions.

P2860

Q26738381-C3BFEF0D-B88B-46C1-9257-8BB3AD79D995 Q26746230-D45A13A8-577E-4424-B945-349AC7EF9805 Q27853360-A62365D5-7B56-4909-A62C-F783D81F859A Q28071903-319C0C58-C7D5-48DB-BE37-DAC4A3A6E88D Q31010216-A57AFD3C-4835-4AD0-A425-C222F88439A3 Q34497467-297684F2-9204-46F7-AFC1-53A76403453E Q36322851-1F57226D-CF6D-41B7-95F4-5FA9282B88B1 Q36427381-6FE658D4-81EA-4565-8F48-E6D4A6A8F119 Q37518624-AF80419F-3321-48AA-BC1F-027A13AFD65C Q37584395-2F000BC1-1881-4E9F-BC1D-222794FA7B1A Q37737536-6D38752F-49FE-4181-9779-35F68C4FF577 Q38653663-0FF9E96B-536F-4039-BCFB-DF1532D91358 Q38809939-2898712B-8F13-4A7F-8481-0E294DFB442E Q38816270-0AE6064B-8DC3-408A-BBC2-D03E92A22737 Q38829087-AB28A1C0-A39C-40DA-8BC8-90DEFA7215F8 Q38991958-310FBD44-575F-449C-9404-2E030111BE4C Q39039088-0DA8C052-5C39-4532-8754-B2052ACFF425 Q39121571-E3DCB188-4215-409A-8F69-8797D45AD17B Q39337110-FEE8941B-249E-404A-BF30-3DCA62E1D4D0 Q40386800-AD8EBE88-76D0-4B3F-99DC-1609C0B7545B Q41593193-C85AA1D8-EDD1-476E-AF79-424EB164F04B Q41820718-C780E4AB-0D36-45EC-A814-D49C3DCBB0B6 Q41879369-B40FD981-248B-4D65-A439-1198F1A65D89 Q42339666-3C74452C-0CEC-446D-897D-46CFF5E954FF Q42367836-0BF7C63E-27B7-43ED-8464-F3766E513A42 Q42369337-F2D031DB-CD9E-4A03-BAF8-F569D2391AC0 Q46915997-B8098F63-7790-40A3-AD9D-0D1BE3EF8007 Q47108604-D87C5334-3E85-4770-A747-D38B06AD49F1 Q47756656-876B4565-09AB-458A-9251-395355BA957A Q48013012-DCEE5CA6-33F9-4BA3-BFF0-AAEF9EEDC3F5 Q49307383-9254FB8A-BA49-4D1C-81D6-9419E2445756 Q49956245-F3C6E61D-4035-45FA-8F90-4B0CDFC961D8 Q50045235-A3AC360F-FD62-478B-82CD-3526E422E649 Q50139910-9E5A2288-D2A2-4DAF-BE67-BD9F61A26834 Q50927730-A7655777-6437-4ADF-A14C-4F3BF8A097FC Q52318443-12423D81-7482-40F3-B05F-0EA5746D4D44 Q53413935-70F495BB-69CE-46F3-A7B2-79BF123B5997 Q53684267-AB307DDA-A1C8-45ED-9DC0-7066F79A69B2 Q54116816-BA071F8B-A774-4CE2-9B8D-9DAF5A1D5C6E Q54942435-FBC452F4-C909-4F4B-9190-D77DFD86D150

P2860

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

http://www.wikidata.org/entity/Q35164218

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Brain metastases in patients w ...... d non-small-cell lung cancers.

@ast

Brain metastases in patients w ...... d non-small-cell lung cancers.

@en

type

label

Brain metastases in patients w ...... d non-small-cell lung cancers.

@ast

Brain metastases in patients w ...... d non-small-cell lung cancers.

@en

prefLabel

Brain metastases in patients w ...... d non-small-cell lung cancers.

@ast

Brain metastases in patients w ...... d non-small-cell lung cancers.

@en

P1433

Q35164218-DEDFA136-4953-427A-A8E8-C55F43A212D8

P1476

Q35164218-E84555F4-F468-4781-B4FD-FBFB2633D3C6

P2093

Q35164218-4094553B-9118-4B28-8BCE-E05F23294D16

Q35164218-642EFEAD-410C-4525-B4F4-13DD7753F7E3

Q35164218-7BC841A6-7C0F-4485-9A5A-9F7E06311E82

Q35164218-C0D43396-D49E-40D2-9297-2232B8195923

Q35164218-F113E2FF-9BD9-42FB-A52F-01D1E43142E2

Q35164218-FC96BFF2-5F7B-48E9-8217-0C64C09444FB

P2860

Q35164218-0B35E44E-6B5D-4933-8D6B-6AE19878371B

Q35164218-22D864B3-8860-44A0-B273-042C85DBA361

Q35164218-2F33373C-0E57-4E2A-B605-B56C4B4C404A

Q35164218-33E080F0-B892-4064-A1E5-23920A25FB24

Q35164218-474CFE84-D041-4C11-8C2E-25BDE6982970

Q35164218-48BC17B3-5764-4E43-99DB-836227AE8E41

Q35164218-6EAAE127-1520-4ADF-AF64-A18C89DBEBAA

Q35164218-7A6D9D9F-1DC0-4044-9148-1D49193A8A19

Q35164218-7D52397F-4DBA-4DA3-8198-D1B88865909E

Q35164218-9064C211-C7F0-4647-B10F-E0FC63BF0054

P304

Q35164218-643BA407-9F8B-46D4-8ECF-8E678092BD77

P31

Q35164218-6EB94C0A-CB93-4071-8225-8A726071436C

P356

Q35164218-5AF67649-18DD-4BF4-9FD6-53C8973A8990

P433

Q35164218-850F59EC-8206-4145-A690-F190DAE55491

P478

Q35164218-41115E02-5CFE-4F77-B033-41A38F2B73F6

P50

Q35164218-001A3AA0-0836-4D2E-A13E-9ECF873E3A35

Q35164218-A83B10F3-EE0B-49CC-8322-B86F861CC6AE

Q35164218-E0C4E1DE-4948-40E4-9538-03E8A5CF672A

Q35164218-EF4A5D16-4845-4FEE-B21A-02B48578114E

Q35164218-FE511605-BC92-40A1-B375-F1E2B9CBFFBB

P577

Q35164218-FE6123AD-2BCD-4067-921C-EF990C4EFFE8

P5875

Q35164218-1D4B288D-7E8B-4198-97A9-669A2A3F587D

P698

Q35164218-0B27A98E-3663-4439-956E-BB6772716A88

P932

Q35164218-19DBD29B-94A5-4F51-8719-3C67BFA8B7C9

P356

J.LUNGCAN.2015.01.020

P1433

P1476

Brain metastases in patients w ...... ed non-small-cell lung cancers

@en

P2093

Anand Mahadevan

http://www.w3.org/2001/XMLSchema#string

Deepa Rangachari

http://www.w3.org/2001/XMLSchema#string

Eric T Wong

http://www.w3.org/2001/XMLSchema#string

Erik J Uhlmann

http://www.w3.org/2001/XMLSchema#string

Mark S Huberman

http://www.w3.org/2001/XMLSchema#string

Norihiro Yamaguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

P304

108-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2015.01.020

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P50

Suzanne E Dahlberg

Paul A VanderLaan

P577

2015-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272358013

http://www.w3.org/2001/XMLSchema#string

P698

25682925

http://www.w3.org/2001/XMLSchema#string

P932

4355240

http://www.w3.org/2001/XMLSchema#string